<DOC>
	<DOCNO>NCT00603330</DOCNO>
	<brief_summary>The present project aim investigate role MSC treatment patient Part 1 : Steroid-refractory grade II-IV acute GVHD . Part 2 : Poor graft function ( PGF ) Part 3 : Low fall donor T-cell chimerism allogeneic HCT . This multicenter phase II study examine feasibility efficacy approach .</brief_summary>
	<brief_title>Mesenchymal Stem Cell Infusion Treatment Steroid-Resistant Acute Graft Versus Host Disease ( GVHD ) Poor Graft Function</brief_title>
	<detailed_description>Part 1 : complete recruitment Part 2 : complete recruitment Part 3 : recruiting</detailed_description>
	<mesh_term>Graft v Host Disease</mesh_term>
	<criteria>Patient eligibility criterion 1 . Male female age . 2 . Previous allogeneic transplantation ( relate unrelated donor , degree HLA matching ) autologous transplantation ( part 2 ) HSC time . 3 . Any source HSC ( marrow , PBSC , cord blood ) condition regimen . 4 . Informed consent give donor his/her guardian minor age . 5 . Additional criterion part protocol : Part 1 : MSC steroidrefractory grade IIIV acute GVHD 1 . Allogeneic transplantation . 2 . Grade IIIV acute GVHD ( see appendix A acute GVHD grading ) de novo follow DLI . 3 . Acute GVHD refractory mPDN 2 mg/kg/day equivalent , define progression GVHD day 3 initiation steroid improvement GVHD day 7 initiation steroid absence complete resolution acute GVHD day 14 initiation steroid relapse acute GVHD steroid taper . 4 . Ongoing therapy Ciclosporine Tacrolimus therapeutic dos . 5 . Patient may receive previously form treatment acute GVHD , new treatment start within 1 month study entry . Part 2 : MSC poor graft function ( PGF ) 1 . Allogeneic autologous transplantation . 2 . Cytopenia 2 3 lineage : Hb &lt; 8.0 g/dL reticulocyte &lt; 1 % , without transfusion Plt &lt; 20,000/µL without transfusion Neutrophils &lt; 500/µL , without GCSF administration OR severe cytopenia 1 lineage : RBC transfusion dependent ( autologous transplantation ; despite EPO administration allogeneic transplantation ) Plt transfusion dependent Neutrophils &lt; 500/µL despite GCSF administration 3 . Cytopenia duration ≥ 2 week beyond day 28 autologous HCT , day 42 ( day 60 cord blood transplantation ) allogeneic HCT . 4 . Cytopenia related CMV infection , myelosuppressive/toxic drug , renal failure , peripheral cell destruction identifiable cause . 5 . In case HLAidentical relate donor full donor chimerism , patient include boost donor CD34+ cell unsuccessful feasible . Part 3 : MSC + DLI poor donor Tcell chimerism 1 . Nonmyeloablative allogeneic transplantation . 2 . Donor Tcell chimerism &lt; 50 % least 2 consecutive week beyond day 21 HCT OR 20 % decrease donor Tcell chimerism second value &lt; 50 % . MSC donor inclusion criterion 1 . Related recipient ( sibling , parent child ) unrelated . 2 . Male female . 3 . Age &gt; 16 yr ( age limit HSC donor ) . 4 . No HLA matching require . 5 . Fulfills generally accept criterion allogeneic HSC donation . 6 . Informed consent give donor his/her guardian minor age . Patient exclusion criterion 1 . HIV positive . 2 . Active uncontrolled infection time schedule MSC infusion . 3 . Relapsing progress malignancy . MSC donor exclusion criterion 1 . HIV positive 2 . Known allergy Lidocaine 3 . If donor HSC donor : risk factor transmissible infectious disease .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Mesenchymal stem cell</keyword>
	<keyword>Graft-versus-host disease</keyword>
	<keyword>Poor graft function</keyword>
	<keyword>Chimerism</keyword>
	<keyword>Hematopoietic cell transplantation recipient</keyword>
	<keyword>Low donor T-cell chimerism</keyword>
</DOC>